PYOIF yields 1.82% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, PYOIF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PYOIF + JNJ for your $10,000?
Promotora y Operadora de Infraestructura, S. A. B. de C. V. engages in the construction, operation, maintenance, financing, and promotion of infrastructure projects in Mexico. Its projects include heavy construction projects, such as toll roads, ports, tunnels, dams, bridges, airports, and railways; industrial construction projects comprising petrochemical, industrial, wastewater treatment, and power generating plants; and urban construction projects, such as parking lots, museums, parks, education centers, buildings, water systems, public transportation systems, landfills, and hospitals. The company produces various asphalt concretes; basalt aggregates, including gravel, sand, seal, ballast, hydraulic base, sub-base, and tepetate; and central guard rails for roads, and various other precast concrete materials, as well as exploits stone aggregates. In addition, the company provides services, such as reception, storage, and shipment of goods; hauling or transfer of goods; loading and unloading ships; container filling and emptying; general cargo storage; and mooring and unmooring of ropes, as well as foreign trade merchandise handling, storage, and custody services. Promotora y Operadora de Infraestructura, S. A. B. de C. V. was founded in 1969 and is based in Mexico City, Mexico.
Full PYOIF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.